Strides Pharma gets DGCI approval to test potential Covid-19 drug
Glenmark was the first Indian firm to get approval from regulator to conduct trials on Favipiravir tablets, which are otherwise used to treat influenza
pharmaceutical firms | Coronavirus
Strides Pharma Science has got approval from the Drug Controller General of India (DCGI) to conduct trials of antiviral drug Favipiravir in India, which is considered a potential treatment for Covid-19.
“We have the approval to conduct human study and we will be starting the trials soon in India,” the Bengaluru-based company said on Thursday.
Favipiravir is a generic version of Avigan, initially developed in Japan to treat influenza. The product is being exported to Gulf countries by Strides to treat patients under a programme for Covid-19. The tablets are being manufactured at Strides’ flagship facility in Bengaluru, which can produce up to six billion units of solid orals annually.
Mumbai-based Glenmark had earlier received approval from the regulator to conduct clinical trials on Favipiravir tablets for Covid-19 patients.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard
First Published: Fri, May 22 2020. 13:57 IST